Andrea Reszegi
Overview
Explore the profile of Andrea Reszegi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Takacs F, Mikala G, Nagy N, Reszegi A, Czeti A, Szaloki G, et al.
Acta Oncol
. 2021 Jan;
60(4):528-530.
PMID: 33491510
Background: The Bcl-2 inhibitor venetoclax has been recently introduced into the treatment of chronic lymphocytic leukemia. Venetoclax is a highly effective drug, however acquired resistance may make long-term treatment challenging....
12.
Baghy K, Reszegi A, Tatrai P, Kovalszky I
Adv Exp Med Biol
. 2020 Aug;
1272:17-38.
PMID: 32845500
The tumor microenvironment plays a determining role in cancer development through a plethora of interactions between the extracellular matrix and tumor cells. Decorin is a prototype member of the SLRP...
13.
Reszegi A, Horvath Z, Karaszi K, Regos E, Postnikova V, Tatrai P, et al.
Biomolecules
. 2020 Aug;
10(8).
PMID: 32824864
Decorin, the prototype member of the small leucine-rich proteoglycan gene family of extracellular matrix (ECM) proteins, acts as a powerful tumor suppressor by inducing the p21 cyclin-dependent kinase inhibitor, as...
14.
Fullar A, Karaszi K, Hollosi P, Lendvai G, Olah L, Reszegi A, et al.
PLoS One
. 2020 Jun;
15(6):e0234873.
PMID: 32559232
Objective: Comparison of human mRNA microarray results from tumor-associated and normal cervical fibroblasts revealed significant TFPI2 downregulation in tumor-associated fibroblasts isolated from cervical cancer, indicating that TFPI2 downregulation may play...
15.
Reszegi A, Horvath Z, Feher H, Wichmann B, Tatrai P, Kovalszky I, et al.
Front Oncol
. 2020 Jun;
10:645.
PMID: 32477937
Hepatocellular carcinoma (HCC) represents one of the most frequent type of primary liver cancers. Decorin, a small leucine-rich proteoglycan of the extracellular matrix, represents a powerful tumor cell growth and...
16.
Horvath Z, Reszegi A, Szilak L, Danko T, Kovalszky I, Baghy K
Cell Signal
. 2019 Jul;
62:109354.
PMID: 31271881
Background: In spite of therapeutic approaches, liver cancer is still one of the deadliest type of tumor in which tumor microenvironment may play an active role in the outcome of...
17.
Regos E, Karaszi K, Reszegi A, Kiss A, Schaff Z, Baghy K, et al.
Pathol Oncol Res
. 2019 Mar;
26(2):813-819.
PMID: 30826971
Liver diseases such as liver cirrhosis, primary and metastatic liver cancers are still a major medical challenge. Syndecan-1 is one of the most important proteoglycans in the liver. Syndecan-1 is...
18.
Mervai Z, Reszegi A, Miklya I, Knoll J, Schaff Z, Kovalszky I, et al.
Pathol Oncol Res
. 2019 Feb;
26(2):727-734.
PMID: 30734151
BPAP is a potent enhancer substance with catecholaminergic and serotoninergic activity in the brain. It was discovered that it is also effective against certain types of experimental cancers, showing the...
19.
Mihaly D, Papp G, Mervai Z, Reszegi A, Tatrai P, Szaloki G, et al.
Exp Biol Med (Maywood)
. 2018 Aug;
243(12):1014-1023.
PMID: 30111166
MiR-206 is a remarkable miRNA because it functions as a suppressor miRNA in rhabdomyosarcoma while at the same time, as previously showed, it can act as an oncomiRNA in SMARCB1...
20.
Regos E, Abdelfattah H, Reszegi A, Szilak L, Werling K, Szabo G, et al.
Matrix Biol
. 2018 Feb;
68-69:474-489.
PMID: 29454902
Increased expression of syndecan-1 is a characteristic feature of human liver cirrhosis. However, no data are available on the significance of this alteration. To address this question we designed a...